Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development

Ads

You May Also Like

IMV Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference

HALIFAX, Nova Scotia, July 25, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq:IMV) (TSX:IMV), a ...

Immuron Receives $1.19M R&D Tax Concession Refund

MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) ...